Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes

Lai, Shih‐Wei; Lin, Hsien-Feng; Lin, Cheng‐Li; Liao, Kuan‐Fu

doi:10.1097/md.0000000000004455

Cited by 9 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICVD mainly includes cerebral infarction and transient ischemic attack. Mortality and disability rate of ICVD are high, seriously affecting human health and bringing financial burden to patients' families and society ( 3 ). The principle of ICVD treatment is to save lives, reduce brain damage, promote the recovery of nerve function, and prevent recurrence ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase on cerebral ischemia in rats

Geng

Dai

2018

Exp Ther Med

View full text Add to dashboard Cite

Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase in the treatment of cerebral ischemia in rat model were investigated. Ninety rats were selected to establish cerebral ischemia model. Animal models were randomly divided into observation group and control group, with 45 rats in each group. Rats in observation group were treated with vascular intervention, and control group was treated with aspirin combined with defibrase. Peak systolic velocity (Vs) and end-diastolic velocity (Vd) were compared between two groups before and after 12 months of treatment. Therapeutic effects were compared before and after 6 months, and before and after 12 months of treatment. Vs and Vd of vascular lesions in observation group at 12 months were reduced after treatment, and were significantly lower than those in control group (p<0.05). After treatment, Vs and Vd in observation group were significantly reduced (p<0.05). There was no significant difference in Vs and Vd values between the groups before treatment (p>0.05). NDS scores in observation group were significantly lower than those in control group at 6 months and 1 year after treatment (p<0.05). There were no significant changes in NDS score at 6 and 12 months after treatment in control group compared with pretreatment group (p>0.05). NDS in observation group was significantly reduced at 6 and 12 months after treatment compared with pretreatment level (p<0.05). One year after treatment, incidence of cerebral infarction and transient ischemic attack and mortality in observation group were significantly lower than those in the control group (p<0.05). Intracranial vascular interventional therapy can achieve satisfactory outcomes in the treatment of cerebral ischemia, and can effectively promote nerve function recovery, and reduce the incidence of cerebrovascular diseases and mortality.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase on cerebral ischemia in rats

Geng

Dai

2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…All comorbidities were diagnosed with ICD-9 codes, although ICD-9 code is only a diagnosing coding system, which has been fully discussed in previous studies. [33–43]…”

Section: Methodsmentioning

confidence: 99%

Population-based cohort study investigating the correlation of diabetes mellitus with pleural empyema in adults in Taiwan

Lai¹,

Lin

Liao

2017

Medicine

Self Cite

View full text Add to dashboard Cite

We assessed the association between diabetes mellitus and the risk of pleural empyema in Taiwan.A population-based retrospective cohort study was conducted using the database of the Taiwan National Health Insurance Program. There were 28,802 subjects aged 20 to 84 years who were newly diagnosed with diabetes mellitus from 2000 to 2010 as the diabetes group and 114,916 randomly selected subjects without diabetes mellitus as the non-diabetes group. The diabetes group and the non-diabetes group were matched by sex, age, comorbidities, and the year of index date. The incidence of pleural empyema at the end of 2011 was estimated. A multivariable Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (95% CI) for pleural empyema associated with diabetes mellitus.The overall incidence of pleural empyema was 1.65-fold higher in the diabetes group than that in the non-diabetes group (1.58 vs 0.96 per 10,000 person-years, 95% CI 1.57-1.72). After adjusting for confounders, a multivariable Cox proportional hazards regression model revealed that the adjusted HR of pleural empyema was 1.71 in subjects with diabetes mellitus (95% CI 1.16-2.51), compared with those without diabetes mellitus. In further analysis, even in the absence of any comorbidity, the adjusted HR was 1.99 for subjects with diabetes mellitus alone (95% CI 1.18-3.38).Diabetic patients confer a 1.71-fold increased hazard of developing pleural empyema. Even in the absence of any comorbidity, the risk remains existent.

show abstract

“…The methodology was adapted from previous studies ( Lai et al, 2016 , 2017j ; Liao et al, 2017b ). It did not need to write published protocol details.…”

Section: Methodsmentioning

confidence: 99%

Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan. This study aimed to investigate the association between DPP-4 inhibitors use and the first episode of ischemic cerebrovascular disease.Methods: We designed a case-control study using the database of the Taiwan National Health Insurance Program. There were 1999 type 2 diabetic subjects aged 20–84 years with the first episode of ischemic cerebrovascular disease from 2000 to 2013 as the cases, and 7996 sex- and age-matched, randomly selected type 2 diabetic subjects aged 20–84 years without any type of cerebrovascular diseases as the matched controls. We estimated the odds ratio (OR) and 95% confidence interval (CI) of ischemic cerebrovascular disease associated with cumulative duration of DPP-4 inhibitors use by the multivariable logistic regression model.Results: After adjustment for confounding variables, the adjusted OR of ischemic cerebrovascular disease was 0.96 (95% CI 0.95, 0.97) in subjects with ever use of DPP-4 inhibitors as increase in use duration for every 1 month, compared with never use. The sub-analysis disclosed that the adjusted ORs of ischemic cerebrovascular disease were 1.57 (95% CI 1.36, 1.80) for subjects with cumulative duration of DPP-4 inhibitors use <1 year, and 0.70 (95% CI 0.57, 0.87) for subjects with cumulative duration of DPP-4 inhibitors use ≥1 year, compared with never use.Conclusion: Our findings suggest that DPP-4 inhibitors use correlates with relative risk reduction of the first episode of ischemic cerebrovascular disease in type 2 diabetic patients in a duration-dependent response. The beneficial effect will be marked when DPP-4 inhibitors use is ≥1 year.

show abstract

Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes

Cited by 9 publications

References 28 publications

Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase on cerebral ischemia in rats

Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase on cerebral ischemia in rats

Population-based cohort study investigating the correlation of diabetes mellitus with pleural empyema in adults in Taiwan

Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study

Contact Info

Product

Resources

About